A Multicenter, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (CRIB)

By Spondylitis Association of America

Monday, May 23, 2016

“The CRIB Study is a clinical research study conducted by UCB BioSciences, Inc., for women who are pregnant and receiving treatment with certolizumab pegol (Cimzia®). The purpose of the study is to determine if Cimzia® crosses from the mother through the placenta to the infant.

If you are pregnant and you and your physician have decided to start or continue treatment with Cimzia® you may be interested in learning more about this study.

You and your physician must have decided on your treatment without considering whether you will take part in the study.

For more information, including eligibility criteria and enrolment information please visit the CRIB Study Page.  

 

This clinical research study is listed on ClinicalTrials.gov

Learn more about participating in clinical research studies

Print

Stay Informed

Text/HTML

Careers

Visit our careers page for available positions

Contact Us

Spondylitis Association of America

16360 Roscoe Blvd.  Ste. 100
Van Nuys, CA 91406

Email

info@spondylitis.org

Information Requests

(800) 777-8189 U.S. only
or (818) 892-1616
*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.

Give With Confidence

Click to verify BBB accreditation and to see a BBB report for Spondylitis Association of America